{"id":1091,"date":"2022-09-13T19:55:10","date_gmt":"2022-09-13T19:55:10","guid":{"rendered":"https:\/\/vimizimhcp-dev-001.azurewebsites.net\/en-us\/vimizim\/?page_id=1091"},"modified":"2023-05-13T10:36:44","modified_gmt":"2023-05-13T10:36:44","slug":"about-vimizim","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/about-vimizim\/","title":{"rendered":"About Vimizim"},"content":{"rendered":"
\n \n
<\/div>\n \n
\n

VIMIZIM\u00ae<\/sup> (elosulfase alfa) helps replace the deficient enzyme in Morquio A1<\/sup><\/h1>\n <\/div>\n<\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n<\/div>\n\n
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t \t\t\t\t\t\t\t<\/div>\n\t\t\t
\n\t\t\t \n
\n \t \n\n \"MOA \n\t
\n \n

At a cellular level, deficient GALNS activity causes GAGs to accumulate in the lysosomes and occupy an increasingly greater area of the cytoplasm, which disrupts normal cell function and activates secondary pathogenic cascades.2,3<\/sup><\/p>\n <\/div>\n<\/div>\n\n

\n \t \n\n \"MOA \n\t
\n \n

VIMIZIM\u00ae<\/sup> (elosulfase alfa) is an exogenous recombinant human enzyme that replaces deficient GALNS.1<\/sup><\/p>\n <\/div>\n<\/div>\n\n

\n \t \n\n \"MOA \n\t
\n \n

Within the lysosome, VIMIZIM increases catabolism of GAGs (KS and C6S)\u2014restoring some cell function.1<\/sup><\/p>\n <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n
\n
\n \n
\n

C6S<\/strong>, chondroitin-6-sulfate; GAGs<\/strong>, glycosaminoglycans; GALNS<\/strong>, N<\/strong>-acetylgalactosamine-6-sulfatase; KS<\/strong>, keratan sulfate; M6PR<\/strong>, mannose 6-phosphate receptor.<\/small><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n

\n
\n
\n \n
\n

The safety and effectiveness of VIMIZIM have not been established in pediatric patients less than 5 years of age.1<\/sup><\/h2>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t\n
\n
\n

Review the early and long-term endurance benefits of VIMIZIM<\/a><\/p>\n <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n
\n\t\t
\n\t\t \t\t\t

References:\n<\/h4>\n\t\t\t\t\t\t
    \n
  1. VIMIZIM [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2019. \n<\/span><\/li>\n
  2. \u00c1lvarez JV, Bravo SB, Garc\u00eda-Vence M, et al. Proteomic Analysis in Morquio A Cells Treated with Immobilized Enzymatic Replacement Therapy on Nanostructured Lipid Systems. Int J Mol Sci<\/em>. 2019;20(18):4610.\n<\/span><\/li>\n
  3. Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochem Res Int<\/em>. 2012;2012:471325.\n<\/span><\/li>\n <\/ol>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-1091","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nEfficacy | About VIMIZIM - VIMIZIM\u00ae (elosulfase alfa) HCP<\/title>\n<meta name=\"description\" content=\"VIMIZIM\u00ae (elosulfase alfa) helps replace deficient GALNS\u2013the cause of progressive, multisystemic consequences.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/about-vimizim\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efficacy | About VIMIZIM - VIMIZIM\u00ae (elosulfase alfa) HCP\" \/>\n<meta property=\"og:description\" content=\"VIMIZIM\u00ae (elosulfase alfa) helps replace deficient GALNS\u2013the cause of progressive, multisystemic consequences.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/about-vimizim\/\" \/>\n<meta property=\"og:site_name\" content=\"BioMarin Vimizim HCP EN-US\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-13T10:36:44+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/about-vimizim\\\/\",\"url\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/about-vimizim\\\/\",\"name\":\"Efficacy | About VIMIZIM - VIMIZIM\u00ae (elosulfase alfa) HCP\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/#website\"},\"datePublished\":\"2022-09-13T19:55:10+00:00\",\"dateModified\":\"2023-05-13T10:36:44+00:00\",\"description\":\"VIMIZIM\u00ae (elosulfase alfa) helps replace deficient GALNS\u2013the cause of progressive, multisystemic consequences.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/about-vimizim\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/about-vimizim\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/about-vimizim\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"About Vimizim\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/#website\",\"url\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/\",\"name\":\"BioMarin Vimizim HCP EN-US\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Efficacy | About VIMIZIM - VIMIZIM\u00ae (elosulfase alfa) HCP","description":"VIMIZIM\u00ae (elosulfase alfa) helps replace deficient GALNS\u2013the cause of progressive, multisystemic consequences.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/about-vimizim\/","og_locale":"en_US","og_type":"article","og_title":"Efficacy | About VIMIZIM - VIMIZIM\u00ae (elosulfase alfa) HCP","og_description":"VIMIZIM\u00ae (elosulfase alfa) helps replace deficient GALNS\u2013the cause of progressive, multisystemic consequences.","og_url":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/about-vimizim\/","og_site_name":"BioMarin Vimizim HCP EN-US","article_modified_time":"2023-05-13T10:36:44+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/about-vimizim\/","url":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/about-vimizim\/","name":"Efficacy | About VIMIZIM - VIMIZIM\u00ae (elosulfase alfa) HCP","isPartOf":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/#website"},"datePublished":"2022-09-13T19:55:10+00:00","dateModified":"2023-05-13T10:36:44+00:00","description":"VIMIZIM\u00ae (elosulfase alfa) helps replace deficient GALNS\u2013the cause of progressive, multisystemic consequences.","breadcrumb":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/about-vimizim\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hcp.biomarin.com\/en-us\/vimizim\/about-vimizim\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/about-vimizim\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/"},{"@type":"ListItem","position":2,"name":"About Vimizim"}]},{"@type":"WebSite","@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/#website","url":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/","name":"BioMarin Vimizim HCP EN-US","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages\/1091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/comments?post=1091"}],"version-history":[{"count":77,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages\/1091\/revisions"}],"predecessor-version":[{"id":2908,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages\/1091\/revisions\/2908"}],"wp:attachment":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/media?parent=1091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}